| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 01/24/2001 | EP1070727A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 01/24/2001 | EP1070711A2 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses |
| 01/24/2001 | EP1070707A1 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 01/24/2001 | EP1070502A2 Compositions and methods for treating or preventing inflammatory diseases |
| 01/24/2001 | EP1070129A2 Dadd, death activator death domain protein |
| 01/24/2001 | EP1070083A1 Crystalline forms of 1s- 1alpha (2s*,3r*), 9alpha]-6, 10-dioxo-n- (2-ethoxy-5 -oxo-tetrahydro-3 -furanyl) -9- (1-isoquinolyl) carbonyl]-amino] octahydro-6h -piridazino 1, 2-a] 1,2] diazepin- 1-carboxamide |
| 01/24/2001 | EP1070069A1 Bicyclic hydroxamic acid derivatives |
| 01/24/2001 | EP1070060A1 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists |
| 01/24/2001 | EP1070058A1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides |
| 01/24/2001 | EP1070049A1 Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| 01/24/2001 | EP1070048A1 Calcilytic compounds |
| 01/24/2001 | EP1069913A1 Gelling ophthalmic compositions containing xanthan gum |
| 01/24/2001 | EP1069901A1 Calcilytic compounds and method of use |
| 01/24/2001 | EP0788513B1 Use of binding agents to cd23 in the treatment of autoimmune diseases |
| 01/24/2001 | EP0712389B1 Therapeutic compound - fatty acid conjugates |
| 01/24/2001 | CN1281458A Purine compounds having PDE IV inhibitory activity and methods of synthesis |
| 01/24/2001 | CN1281451A Benzamine derivatives |
| 01/24/2001 | CN1281444A Azulene hydroxamic acid derivatives as metalloprotein inhibitors |
| 01/24/2001 | CN1281441A Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors |
| 01/24/2001 | CN1281433A Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors |
| 01/24/2001 | CN1281432A Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing same |
| 01/24/2001 | CN1281430A N-alkanoylphenylalanine derivatives |
| 01/24/2001 | CN1281367A Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 01/24/2001 | CN1281362A Novel combination medicine |
| 01/24/2001 | CN1280847A Process for preparing medical wine to treat rheumatic arthritis |
| 01/24/2001 | CN1280846A Process for preparing medicine to cure rheumatoid arthritis |
| 01/24/2001 | CN1280841A Medicine for treating hepatitis B and rheumatoid diseases |
| 01/24/2001 | CN1061050C Ureido derivatives of naththalenephosphonic acids and process for their preparation |
| 01/24/2001 | CN1061049C Sulfur-containing phosphonate compounds, pharmaceutical compositions and use thereof |
| 01/24/2001 | CN1061044C Tricyclic 5,6-dihydro-9H-pyrazolo [3,4-C]-1,2,4-triaolo [4,3-alpha] pyridines |
| 01/24/2001 | CN1061042C Adhesion receptor antagonists |
| 01/24/2001 | CN1061041C Piperidine derivatives |
| 01/24/2001 | CN1061036C Substituted pyrazolyl benzenesulfonamides for treating inflammation |
| 01/23/2001 | US6177561 Preparation of acid amides and metallization of compounds |
| 01/23/2001 | US6177560 Direct esterification of the 17 hydroxyl group without prior protection of the free 11 hydroxy function. |
| 01/23/2001 | US6177545 Antibody which preferentially binds an epitope of an enzymatic protein; for diagnosis of time events in tumor propagation and metastasis, autoimmune diseases, kidney defects and atherosclerotic injury |
| 01/23/2001 | US6177470 Prostaglandin synthesis |
| 01/23/2001 | US6177467 Tumor necrosis factor antagonist |
| 01/23/2001 | US6177444 Allosteric adenosine receptor modulators |
| 01/23/2001 | US6177429 Dihydropyrazine derivatives as NPY antagonists |
| 01/23/2001 | US6177428 Treatment of sexual dysfunction; stimulation of endogenous nitrogen monoxide synthesis |
| 01/23/2001 | US6177426 Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors |
| 01/23/2001 | US6177425 Stereospecific enantiomer having antiinflammatory and neutrophil elastase inhibiting activity; for treatment of chronic bronchitis in humans or animals |
| 01/23/2001 | US6177077 TNT inhibitors for the treatment of neurological disorders |
| 01/23/2001 | CA2196885C Carboxamide compounds (changed to n-(2-(pyrrolidinyl-1)-1-phenylethyl) acetamides as kappa receptor antagonists) |
| 01/23/2001 | CA2191790C Biaromatic compounds containing an adamantyl group in para position; pharmaceutical and cosmetic compositions containing them and use thereof |
| 01/23/2001 | CA2021340C Cyclic vinylogous n-hydroxy-n-methylureas useful as 5-lipoxygenase inhibitors |
| 01/21/2001 | CA2314373A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their thereapeutic uses |
| 01/18/2001 | WO2001004341A1 Method for producing oligopolysaccharides |
| 01/18/2001 | WO2001004326A1 Tankyrase homolog protein (thp), nucleic acids, and methods related to the same |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004290A1 Triplex-forming oligonucleotides and their use in therapy |
| 01/18/2001 | WO2001004114A1 Diesters of maleic or fumaric acid |
| 01/18/2001 | WO2001004102A1 Quinazoline derivatives |
| 01/18/2001 | WO2001004099A1 Benzoylpyridazines |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003712A1 Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement |
| 01/18/2001 | WO2001003710A1 Analgesic from snake venom |
| 01/18/2001 | WO2001003696A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | WO2000063415A8 Dna encoding the human vanilloid receptor vr1 |
| 01/18/2001 | WO2000063234A3 Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists |
| 01/18/2001 | WO2000062744A3 Skin care compositions containing combination of skin care actives |
| 01/18/2001 | WO2000059285A3 NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE |
| 01/18/2001 | WO2000055180A3 Human lung cancer associated gene sequences and polypeptides |
| 01/18/2001 | WO2000035492A3 Vitronectin receptor antagonist pharmaceuticals |
| 01/18/2001 | WO1999050403A3 Method and reagents for the treatment of diseases or conditions related to molecules involved in angiogenic responses |
| 01/18/2001 | DE19933173A1 Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ Cyclic peptide derivatives as inhibitors of the integrin alpha¶v¶beta¶6¶ |
| 01/18/2001 | DE19932796A1 Diacylhydrazinderivate Diacylhydrazinderivate |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2378595A1 Benzoylpyridazines |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378562A1 Method for producing oligopolysaccharides |
| 01/18/2001 | CA2378291A1 Quinazoline derivatives |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2377914A1 Analgesic from snake venom |
| 01/18/2001 | CA2377502A1 Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 01/17/2001 | EP1069182A1 Alleviation of symptoms associated with inflammatory disease states, using antibodies to CD18 |
| 01/17/2001 | EP1069124A1 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
| 01/17/2001 | EP1069114A2 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/17/2001 | EP1069106A2 Dimethyl-(3-aryl-but-3-enyl) amine derivatives with analgesic activity |
| 01/17/2001 | EP1068868A2 Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration |
| 01/17/2001 | EP1068867A2 Pharmaceutical tablet comprising an NSAID and misoprostol |
| 01/17/2001 | EP1068338A2 Enhanced prodrug activation |
| 01/17/2001 | EP1068315A2 Therapeutic agent for ngf |
| 01/17/2001 | EP1068308A1 Secreted proteins and polynucleotides encoding them |
| 01/17/2001 | EP1068224A2 Pharmaceuticals for the imaging of angiogenic disorders |
| 01/17/2001 | EP1068221A2 Template associated npy y2-receptor agonists |
| 01/17/2001 | EP1068212A1 THIAZOLO 4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| 01/17/2001 | EP1068207A1 AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES |
| 01/17/2001 | EP1068206A1 Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
| 01/17/2001 | EP1068205A1 Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands |
| 01/17/2001 | EP1068200A1 2,4,4-trisubstituted-1,3-dioxolane antifungals |
| 01/17/2001 | EP1068194A1 Pde iv inhibiting pyridine derivatives |
| 01/17/2001 | EP1068187A1 Pyrazole inhibitors of cytokine production |
| 01/17/2001 | EP1068180A1 Process for alkylating hindered sulfonamides useful in the production of matrix metalloprotenase inhibitors |
| 01/17/2001 | EP1067915A2 Device for the transdermal delivery of diclofenac |
| 01/17/2001 | EP1067894A2 Protease inhibitors |